Trust us

NIMGENETICS ESTABLISHED

NIMGenetics was established by Dr Enrique Samper, Dr Juan Cruz Cigudosa and Dr Sara Álvarez as the main founding partners. In just one year, NIMGenetics positioned itself as a leading and pioneering Spanish genome analysis company, using Array CGH genetic testing technology, and was endorsed by the Centre for the Development of Industrial Technology (CDTI).

FIRST AWARDS

We were awarded the "Best Growth Project in SMEs" (IE Business School) and positioned ourselves as the only company in southern Europe certified by Agilent Technologies. In conjunction with TiGENIX, we won the INNPACTO- ASCIVAR Project to design a specific genetic diagnostic array for cell therapy.

REDESIGN AND LAUNCH OF NEW SERVICES WITH QUALITY CERTIFICATIONS

We developed KaryoNIM^® Postnatal, launched a new KaryoNIM^® Prenatal test and obtained, for the first time, the Quality Certification from the Cytogenetics European Quality Association, as a certified genetic diagnostic laboratory using Array CGH methods.

CONTINUED INNOVATION BY NIMGENETICS

We continued to develop new services targeting different neurological diseases and cancers: KaryoNIM^® Autism 180K, KaryoNIM^® Stem Cells, OncoNIM® Hereditary Cancer and OncoNIM® Cancer Diagnostics.

CREATION OF TRISONIM®, THE “PRENATAL REVOLUTION”

NIMGenetics revolutionised prenatal diagnosis by launching the first non-invasive prenatal screening test for pregnant women in Spain: TrisoNIM® (in collaboration with the Beijing Genomics Institute, BGI).

AWARD FOR TRISONIM

TrisoNIM^®, our non-invasive prenatal test, was recognised as one of the 100 Best Ideas 2012 for the health category, awarded by Actualidad Económica business magazine.

THE START OF OUR GLOBALISATION

BGI invited us to the International Congress on Non-Invasive Fetal Diagnosis in Prague, and Agilent Technologies to its California head office as expert advisers on In situ hybridisation technology.

INTERNATIONAL EXPANSION

Always wanting to go further, NIMGenetics invested significant resources to reach new markets, such as Colombia, Chile, Peru, Paraguay, Uruguay and Portugal, as a spearhead for our international positioning and development.

WELCOME TO BRAZIL!

NIMGenetics Brazil became a reality, and we established a physical presence in one of the largest markets in the world.

INNOVATIVE SME RECOGNITION 2016

The Innovative Companies Forum recognised us as the Innovative SME of 2016. A proud moment for the NIMGenetics team!

ISO 15189 ACCREDITATION FOR KARYONIM POSTNATAL 60K

NIMGenetics had already been ISO 15189-accredited for the array CGH test since June 2015. We were the first laboratory in Spain to show compliance with this standard, which objectively and independently accredits and demonstrates a laboratory's commitment to quality and technical competence (ENAC accreditation number 1212/LE2336).

7 MILLION EURO INVESTMENT FROM APPOSITE CAPITAL

Apposite Capital committed to our great FAMILY by investing 7 million Euros! Read the full article here.

OPENING OF NEW OFFICES IN ALCOBENDAS (MADRID)

In addition to our headquarters in Madrid Science Park, we opened new offices in Alcobendas, in the Vega Norte Business Complex. Photo courtesy of Villar Soba Inversiones.

INNOVATIVE SME ACCREDITATION

The Spanish Ministry of Economy and Competitiveness renewed our Innovative SME seal for our work in the field of Research, Development and Technological Innovation.

ISO 9001:2015 CERTIFICATION

Our management system was certified by Bureau Veritas, in accordance with ISO 9001:2015 Standard. The scope applies to providing diagnostic genetic testing services in pre-analytical, analytical and post-analytical stages for the specialities of genomics, non-invasive prenatal testing and molecular diagnostics.

COMMITTED TO EARLY GYNAECOLOGICAL CANCER DETECTION

NIMGenetics reached agreements for the distribution of GynTect (2019), which allowed us to fully enter the field of early gynaecological cancer detection and prevention.

STILL COMMITTED TO QUALITY

NIMGenetics was accredited by ENAC for the ISO 15189 Standard in fetal aneuploidy screening (chromosomes 13, 18, 21, X and Y), and in maternal blood fetal sex determination through massive parallel sequencing (NGS), which corresponds to the TrisoNIM Basic and Basic Plus tests.

REVOLUTION IN PRENATAL DIAGNOSIS

We added TrisoNIM NeoSeq to our range of maternal blood fetal DNA tests, taking a qualitative step forward in non-invasive prenatal genetic testing by including dominant monogenic disorders.